高级检索
当前位置: 首页 > 详情页

Continuous administration of voriconazole enhances therapeutic effect for recalcitrant fungal keratitis.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Cornea, Beijing Aier Intech Eye Hospital, Beijing, China. [2]Aier Cornea Institute, Beijing, China. [3]506624Aier School of Ophthalmology, Central South University, Changsha, Hunan, P.R. China. [4]NeuVision Medical Institute, Arizona, USA. [5]Department of Ophthalmology and Visual Science, College of Medicine, 12216University of Arizona, Arizona, USA.
出处:
ISSN:

摘要:
To evaluate the therapeutic effect of incorporating continuous administration of voriconazole in the treatment of recalcitrant fungal keratitis.In this prospective case study, 5 consecutive patients (5 eyes) with fungal keratitis were treated with a standard protocol after the failing maximal conventional medical treatment. The protocol involved continuous lavage of the ulcer with 1% voriconazole through an irrigator for 2 h, twice a day, combined with local and systemic antifungals. Visual acuity, slit lamp findings of the ulcer, and fungal hyphae density by confocal microscope were documented, respectively.In 4 patients, the clinical symptoms and slit lamp examination were significantly improved after only 3 days of treatment. The hyphae were shown to decrease in number and morphologically fragmented in corneal stroma by confocal microscopy. After the infection was controlled, 2 cases required further keratoplasty. In one case, the treatment was deemed ineffective and a conjunctival flap had to be created to help control the infection. In all 5 patients, the best spectacle-corrected visual acuity had improved after treatment. With more than 3 months of follow-up, no recurrence of infection was seen in any cases.Our treatment protocol demonstrated improvement in the treatment of clinically resistant fungal keratitis. Continuous lavage of voriconazole is easy to be implemented and well-tolerated by patients. Modification of the current protocol should be further explored to optimize the therapeutic effectiveness in future.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 眼科学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 眼科学
第一作者:
第一作者机构: [1]Department of Cornea, Beijing Aier Intech Eye Hospital, Beijing, China.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Cornea, Beijing Aier Intech Eye Hospital, Beijing, China. [2]Aier Cornea Institute, Beijing, China. [3]506624Aier School of Ophthalmology, Central South University, Changsha, Hunan, P.R. China. [4]NeuVision Medical Institute, Arizona, USA. [5]Department of Ophthalmology and Visual Science, College of Medicine, 12216University of Arizona, Arizona, USA. [*1]No.12 (Panjiayuan Building), Panjiayuan Alley South, Chaoyang District, Beijing, China [*2]Cornea Associates, 6422 E. Speedway Boulevard, Suite 100, Tucson, AZ, USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:23624 今日访问量:3 总访问量:1285 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)